Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Clinical trial NCT05847764 · UNKNOWN

Trial details

NCT number: NCT05847764
Sponsor: Sun Yat-sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer ERBB2 Mutation-Related Tumors RC48 Disitamab Vedotin

Start date: 2023-05-01
Primary completion: 2024-10-01
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.